Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://chungkong.nl
Are you over 18 and want to see adult content?
A complete backup of https://bestadventuretravel.us
Are you over 18 and want to see adult content?
A complete backup of https://roofos.ru
Are you over 18 and want to see adult content?
A complete backup of https://syattfitness.com
Are you over 18 and want to see adult content?
A complete backup of https://lccc.edu
Are you over 18 and want to see adult content?
A complete backup of https://leocaillard.com
Are you over 18 and want to see adult content?
A complete backup of https://wein-plus.eu
Are you over 18 and want to see adult content?
A complete backup of https://smartafisha.ru
Are you over 18 and want to see adult content?
A complete backup of https://terradegossos.com
Are you over 18 and want to see adult content?
A complete backup of https://1xbetes.info
Are you over 18 and want to see adult content?
A complete backup of https://thewhaletrail.org
Are you over 18 and want to see adult content?
A complete backup of https://userlytics.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of czechgaysolarium.com
Are you over 18 and want to see adult content?
A complete backup of zapinterlations.com
Are you over 18 and want to see adult content?
A complete backup of bigoliveapkmod.com
Are you over 18 and want to see adult content?
A complete backup of queenletiziastyle.com
Are you over 18 and want to see adult content?
A complete backup of smashingpumpkins.com
Are you over 18 and want to see adult content?
A complete backup of biologyjunction.com
Are you over 18 and want to see adult content?
Text
prioritize HCV and
LANDMARK TB TRIALS RESULTS PUBLISHED IN NEW ENGLAND A Shorter Regimen Containing Rifapentine and Moxifloxacin Studied by CDC and NIH Can Cure TB in Four Months . CONTACT: Mike Frick (New York), mike.frick@treatmentactiongroup.org May 6, 2021—Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six LONG-ACTING INJECTABLE CABOTEGRAVIR FOR HIV PRE-EXPOSURE Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved. HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB MR. WARREN C. KOCMOND PRESIDENT AND CHIEF OPERATING Mr. Warren C. Kocmond President and Chief Operating Officer Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 United States CC: Mr. Philippe Jacon, President, Global Access, Cepheid A BRIEF LOOK AT THE HIV TESTING AND PREVENTION TOOLBOX A Brief Look at the HIV Testing and Prevention Toolbox 3 Options for both HIV positive and HIV negative Condoms Condoms work if used correctly and consistently. PEPFAR COP21 TECHINCAL GUIDANCE (P106) Programmatic Overlap: HIV and Hypertension Programs •Potential for SAANE (simple, algorithmic, affordable, non- toxic, effective) guidelines for diagnosis and treatment •Feasible task shifting and self–or community-care •Decentralizable models of care •Lifelong oral medications •Clear indicators for monitoring patient andprogram success
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCES Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
LANDMARK TB TRIALS RESULTS PUBLISHED IN NEW ENGLAND A Shorter Regimen Containing Rifapentine and Moxifloxacin Studied by CDC and NIH Can Cure TB in Four Months . CONTACT: Mike Frick (New York), mike.frick@treatmentactiongroup.org May 6, 2021—Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six LONG-ACTING INJECTABLE CABOTEGRAVIR FOR HIV PRE-EXPOSURE Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved. HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB MR. WARREN C. KOCMOND PRESIDENT AND CHIEF OPERATING Mr. Warren C. Kocmond President and Chief Operating Officer Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 United States CC: Mr. Philippe Jacon, President, Global Access, Cepheid A BRIEF LOOK AT THE HIV TESTING AND PREVENTION TOOLBOX A Brief Look at the HIV Testing and Prevention Toolbox 3 Options for both HIV positive and HIV negative Condoms Condoms work if used correctly and consistently. PEPFAR COP21 TECHINCAL GUIDANCE (P106) Programmatic Overlap: HIV and Hypertension Programs •Potential for SAANE (simple, algorithmic, affordable, non- toxic, effective) guidelines for diagnosis and treatment •Feasible task shifting and self–or community-care •Decentralizable models of care •Lifelong oral medications •Clear indicators for monitoring patient andprogram success
COMMUNITY-BASED ARTICLES AND REPORTS Community-Based Articles and Reports. Refined Mapping of HIV’s Reservoir Could Aid in Cure Research – Benjamin Ryan, POZ Magazine, October 12, 2020. A Landscape Analysis of HIV Cure-Related Clinical Research in 2019 – Liz Barr and Richard Jefferys, Treatment Action Group, October 1, 2020. Treatment Action Group Mourns the Loss ofTimothy
ABOUT US – TREATMENT ACTION GROUP CONTACT Treatment Action Group 90 Broad Street, Suite 2503 New York, NY 10004 212-253-7922 tag@treatmentactiongroup.org WWW.TREATMENTACTIONGROUP.ORG www.treatmentactiongroup.org LONG-ACTING INJECTABLE CABOTEGRAVIR FOR HIV PRE-EXPOSURE Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial. RESEARCH TOWARD A CURE TRIALS A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s). N-NITROSAMINES AND TUBERCULOSIS 5 N-nitrosamines and rifapentine Currently, only two companies produce quality- carcinogenicity, and assured rifapentine: Sanofi and Macleods. The N-nitrosamine impurity identified in rifapentine, HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1,LINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. AN ACTIVIST’S GUIDE TO TUBERCULOSIS DIAGNOSTIC TOOLS 2 Research Challenges little investment in basic science for identifying new markers of TB infection, disease, improvement, or worsening that could eventually be used in diagnostic tests (basic science for TB received just USD $139.8 million in 2015, out of a projected need of $455 million); WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCES Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
COMMUNITY-BASED ARTICLES AND REPORTS Community-Based Articles and Reports. Refined Mapping of HIV’s Reservoir Could Aid in Cure Research – Benjamin Ryan, POZ Magazine, October 12, 2020. A Landscape Analysis of HIV Cure-Related Clinical Research in 2019 – Liz Barr and Richard Jefferys, Treatment Action Group, October 1, 2020. Treatment Action Group Mourns the Loss ofTimothy
RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved. HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TBLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted MR. WARREN C. KOCMOND PRESIDENT AND CHIEF OPERATING Mr. Warren C. Kocmond President and Chief Operating Officer Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 United States CC: Mr. Philippe Jacon, President, Global Access, Cepheid A BRIEF LOOK AT THE HIV TESTING AND PREVENTION TOOLBOX A Brief Look at the HIV Testing and Prevention Toolbox 3 Options for both HIV positive and HIV negative Condoms Condoms work if used correctly and consistently. PEPFAR COP21 TECHINCAL GUIDANCE (P106) Programmatic Overlap: HIV and Hypertension Programs •Potential for SAANE (simple, algorithmic, affordable, non- toxic, effective) guidelines for diagnosis and treatment •Feasible task shifting and self–or community-care •Decentralizable models of care •Lifelong oral medications •Clear indicators for monitoring patient andprogram success
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCES Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
COMMUNITY-BASED ARTICLES AND REPORTS Community-Based Articles and Reports. Refined Mapping of HIV’s Reservoir Could Aid in Cure Research – Benjamin Ryan, POZ Magazine, October 12, 2020. A Landscape Analysis of HIV Cure-Related Clinical Research in 2019 – Liz Barr and Richard Jefferys, Treatment Action Group, October 1, 2020. Treatment Action Group Mourns the Loss ofTimothy
RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved. HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TBLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted MR. WARREN C. KOCMOND PRESIDENT AND CHIEF OPERATING Mr. Warren C. Kocmond President and Chief Operating Officer Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 United States CC: Mr. Philippe Jacon, President, Global Access, Cepheid A BRIEF LOOK AT THE HIV TESTING AND PREVENTION TOOLBOX A Brief Look at the HIV Testing and Prevention Toolbox 3 Options for both HIV positive and HIV negative Condoms Condoms work if used correctly and consistently. PEPFAR COP21 TECHINCAL GUIDANCE (P106) Programmatic Overlap: HIV and Hypertension Programs •Potential for SAANE (simple, algorithmic, affordable, non- toxic, effective) guidelines for diagnosis and treatment •Feasible task shifting and self–or community-care •Decentralizable models of care •Lifelong oral medications •Clear indicators for monitoring patient andprogram success
COMMUNITY-BASED ARTICLES AND REPORTS Community-Based Articles and Reports. Refined Mapping of HIV’s Reservoir Could Aid in Cure Research – Benjamin Ryan, POZ Magazine, October 12, 2020. A Landscape Analysis of HIV Cure-Related Clinical Research in 2019 – Liz Barr and Richard Jefferys, Treatment Action Group, October 1, 2020. Treatment Action Group Mourns the Loss ofTimothy
WWW.TREATMENTACTIONGROUP.ORG www.treatmentactiongroup.org RESEARCH TOWARD A CURE TRIALS A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).IN MEMORIAM
June 3, 2021 – We at Treatment Action Group (TAG) deeply mourn the loss of Marco Castro-Bojorquez, a visionary HIV and human rights activist, artist, and filmmaker. Marco’s light shined brightly throughout his work and lifted up all around him. His work at the intersection of HIV and migrant and undocumented rights, and economic and language justice, was especially important. N-NITROSAMINES AND TUBERCULOSIS 5 N-nitrosamines and rifapentine Currently, only two companies produce quality- carcinogenicity, and assured rifapentine: Sanofi and Macleods. The N-nitrosamine impurity identified in rifapentine, HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and for HIV PREVENTION INDICATORS HIV Prevention Indicators 3 rather than other more proven tools (PEP, syringe access, comprehensive sexual education, structural-level interventions, etc.).LINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. AN ACTIVIST’S GUIDE TO TUBERCULOSIS DIAGNOSTIC TOOLS 2 Research Challenges little investment in basic science for identifying new markers of TB infection, disease, improvement, or worsening that could eventually be used in diagnostic tests (basic science for TB received just USD $139.8 million in 2015, out of a projected need of $455 million); WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCES Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.LINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB PEPFAR COP21 TECHINCAL GUIDANCE (P106) Programmatic Overlap: HIV and Hypertension Programs •Potential for SAANE (simple, algorithmic, affordable, non- toxic, effective) guidelines for diagnosis and treatment •Feasible task shifting and self–or community-care •Decentralizable models of care •Lifelong oral medications •Clear indicators for monitoring patient andprogram success
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICING Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCES Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.LINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB PEPFAR COP21 TECHINCAL GUIDANCE (P106) Programmatic Overlap: HIV and Hypertension Programs •Potential for SAANE (simple, algorithmic, affordable, non- toxic, effective) guidelines for diagnosis and treatment •Feasible task shifting and self–or community-care •Decentralizable models of care •Lifelong oral medications •Clear indicators for monitoring patient andprogram success
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICING Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
MISSION & VISION
Mission Statement: Treatment Action Group (TAG) is an independent, activist, and community-based research and policy think tank committed to racial, gender, and LGBTQ+ equity; social justice; and liberation, fighting to end HIV, tuberculosis (TB), and hepatitis C virus (HCV). TAG catalyzes open collective action by affected communities WWW.TREATMENTACTIONGROUP.ORG www.treatmentactiongroup.org 2020 PIPELINE REPORT Welcome to the 2020 Pipeline Report. Our annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), andtuberculosis (TB).
CONFERENCES, MEETINGS, AND EVENTS 11th IAS Conference on HIV Science in 2021 – Berlin, Germany (TBC), July 18-21, 2021 Pre- and Post-CROI Community HIV Cure Research Workshop – March 4, 5 & 16, 2021 2021 Conference on Retroviruses & Opportunistic Infections – March 6-10, LONG-ACTING INJECTABLE CABOTEGRAVIR FOR HIV PRE-EXPOSURE Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial. RESEARCH TOWARD A CURE MAY 17, 2021 Research Toward a Cure May 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved. HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
N-NITROSAMINES AND TUBERCULOSIS 5 N-nitrosamines and rifapentine Currently, only two companies produce quality- carcinogenicity, and assured rifapentine: Sanofi and Macleods. The N-nitrosamine impurity identified in rifapentine,HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and forANNETTE GAUDINO
Annette’s experience extends from bench to bedside: she has worked in a molecular biology research lab, and as a licensed speech, language and swallowing therapist. Annette is an ACT UP veteran with nearly 30 years of experience in the LGBT/Queer, HIV/AIDS, harm reduction and related social justice movements. Annette is a proudBronxite and a
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCES Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and forLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICING Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCES Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and forLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICING Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
2020 ANNUAL REPORT
June 2021 marks the 40 th anniversary of the U.S. government’s first reports of what later came to be known as AIDS. Over those four decades, 76 million people became infected with HIV, and over 33 million have died from it. Thanks to research and activism, more than 26 million of the world’s 38 million people living with HIV are receiving life-saving treatment. WWW.TREATMENTACTIONGROUP.ORG www.treatmentactiongroup.org HISTORY – TREATMENT ACTION GROUP History. Treatment Action Group had its origins in the AIDS activist organization, ACT UP (the AIDS Coalition to Unleash Power). In January 1992, members of the Treatment and Data Committee of ACT UP left the parent group to create a nonprofit organization focused on accelerating treatment research. RESEARCH TOWARD A CURE TRIALS A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).IN MEMORIAM
June 3, 2021 – We at Treatment Action Group (TAG) deeply mourn the loss of Marco Castro-Bojorquez, a visionary HIV and human rights activist, artist, and filmmaker. Marco’s light shined brightly throughout his work and lifted up all around him. His work at the intersection of HIV and migrant and undocumented rights, and economic and language justice, was especially important. RESEARCH IN ACTION AWARDS 2020 Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progressand justice.
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. STAFF – TREATMENT ACTION GROUP CONTACT Treatment Action Group 90 Broad Street, Suite 2503 New York, NY 10004 212-253-7922 tag@treatmentactiongroup.org 2020 TAG ANNUAL REPORT PROGRESS IN THE FIGHT PROGRESS IN THE FIGHT For Better Treatment, Prevention, a Vaccine, and a Cure for HIV, Tuberculosis, and Hepatitis C Virus 2020 TAG ANNUALREPORT
ADHERENCE FACT SHEET Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health. This fact sheet is about adherence to hepatitis C treatment. It may be helpful for other medications, whether you are taking them for a short time,or for
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCESTREATMENT ACTION GROUP NYCTREATMENT ACTION GROUP TAGTREATMENT GROUP DEFINITIONLATENT TUBERCULOSIS TREATMENT CDCLATENT TUBERCULOSIS TREATMENT GUIDELINESTUBERCULOSIS TREATMENTCHART
Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and forLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICINGHOW TO LOWER DRUGPRICES
Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCESTREATMENT ACTION GROUP NYCTREATMENT ACTION GROUP TAGTREATMENT GROUP DEFINITIONLATENT TUBERCULOSIS TREATMENT CDCLATENT TUBERCULOSIS TREATMENT GUIDELINESTUBERCULOSIS TREATMENTCHART
Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and forLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICINGHOW TO LOWER DRUGPRICES
Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
2020 ANNUAL REPORT
June 2021 marks the 40 th anniversary of the U.S. government’s first reports of what later came to be known as AIDS. Over those four decades, 76 million people became infected with HIV, and over 33 million have died from it. Thanks to research and activism, more than 26 million of the world’s 38 million people living with HIV are receiving life-saving treatment. WWW.TREATMENTACTIONGROUP.ORG www.treatmentactiongroup.org HISTORY – TREATMENT ACTION GROUP History. Treatment Action Group had its origins in the AIDS activist organization, ACT UP (the AIDS Coalition to Unleash Power). In January 1992, members of the Treatment and Data Committee of ACT UP left the parent group to create a nonprofit organization focused on accelerating treatment research. RESEARCH TOWARD A CURE TRIALS A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).IN MEMORIAM
June 3, 2021 – We at Treatment Action Group (TAG) deeply mourn the loss of Marco Castro-Bojorquez, a visionary HIV and human rights activist, artist, and filmmaker. Marco’s light shined brightly throughout his work and lifted up all around him. His work at the intersection of HIV and migrant and undocumented rights, and economic and language justice, was especially important. RESEARCH IN ACTION AWARDS 2020 Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progressand justice.
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. STAFF – TREATMENT ACTION GROUP CONTACT Treatment Action Group 90 Broad Street, Suite 2503 New York, NY 10004 212-253-7922 tag@treatmentactiongroup.org 2020 TAG ANNUAL REPORT PROGRESS IN THE FIGHT PROGRESS IN THE FIGHT For Better Treatment, Prevention, a Vaccine, and a Cure for HIV, Tuberculosis, and Hepatitis C Virus 2020 TAG ANNUALREPORT
ADHERENCE FACT SHEET Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health. This fact sheet is about adherence to hepatitis C treatment. It may be helpful for other medications, whether you are taking them for a short time,or for
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCESTREATMENT ACTION GROUP NYCTREATMENT ACTION GROUP TAGTREATMENT GROUP DEFINITIONLATENT TUBERCULOSIS TREATMENT CDCLATENT TUBERCULOSIS TREATMENT GUIDELINESTUBERCULOSIS TREATMENTCHART
Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and forLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICINGHOW TO LOWER DRUGPRICES
Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
WELCOME! – TREATMENT ACTION GROUPABOUT USCOVID-19HIVHCVTBRESOURCESTREATMENT ACTION GROUP NYCTREATMENT ACTION GROUP TAGTREATMENT GROUP DEFINITIONLATENT TUBERCULOSIS TREATMENT CDCLATENT TUBERCULOSIS TREATMENT GUIDELINESTUBERCULOSIS TREATMENTCHART
Welcome! – Treatment Action Group. TAG is seeking a consultant to advance strategic policy-advocacy efforts for global HCV/harm reduction funding. The consultant will be responsible for engaging policymakers, tracking donor strategies, and executing targeted campaigns in collaboration with TAG and HCV coalition partners toprioritize HCV and
HEPATITIS C VIRUS (HCV) DIAGNOSTICS FACT SHEET A viral-load test (called HCV RNA) is used to check for hepatitis C in the bloodstream. Usually, hepatitis C virus can be found in a person’s bloodstream two weeks after he or she becomes infected. *Except in case of recent risk (within six months) or in people with a weakened immune system. **During the first six months after HCVinfection
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. RESEARCH TOWARD A CURE MARCH 17, 2021 Research Toward a Cure March 17, 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.HARVONI FACT SHEET
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old. Harvoni is also approved for people with HCV genotype 1 who have advanced (called decompensated) cirrhosis, and forLINDSAY MCKENNA
Lindsay joined TAG in 2012 as an Assistant TB/HIV Project Officer and moved on to becoming a TB/HIV Project Officer, then Senior TB/HIV Project Officer, prior to her current role. She received her Master of Public Health from SUNY Stony Brook University, and her Bachelor of Arts in Public Health Studies from Johns Hopkins University. THE LAM TEST: VITAL FOR DIAGNOSING TB IN PEOPLE WITH 2 THE LAM TEST For the first time ever, there is a test that can easily diagnose active TB in people with advanced HIV.9 In 2015, the World Health Organization (WHO) recommended the use of a new test to efficiently detect TB UNIVERSAL HEALTH CARE AND PRESCRIPTION DRUG PRICINGHOW TO LOWER DRUGPRICES
Universal Health Care and Prescription Drug Pricing. Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success. If there is one thing the majority of Americans agree on,it’s that health
STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH (SSDHS) Structural and Social Determinants of Health (SSDHs) 3 to one in 45 and for Black women one in 18. LGBTQ populations are also disproportionally impacted AN ACTIVIST’S GUIDE TO TUBERCULOSIS DRUGS 2 Approved: approved by a stringent regulatory authority for use against TB Accelerated or conditional approval: allows a drug to enter the market based on phase II data (surrogate endpoints), but requires the sponsor to conduct and submit data from a phase III trial(clinical
2020 ANNUAL REPORT
June 2021 marks the 40 th anniversary of the U.S. government’s first reports of what later came to be known as AIDS. Over those four decades, 76 million people became infected with HIV, and over 33 million have died from it. Thanks to research and activism, more than 26 million of the world’s 38 million people living with HIV are receiving life-saving treatment. WWW.TREATMENTACTIONGROUP.ORG www.treatmentactiongroup.org HISTORY – TREATMENT ACTION GROUP History. Treatment Action Group had its origins in the AIDS activist organization, ACT UP (the AIDS Coalition to Unleash Power). In January 1992, members of the Treatment and Data Committee of ACT UP left the parent group to create a nonprofit organization focused on accelerating treatment research. RESEARCH TOWARD A CURE TRIALS A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).IN MEMORIAM
June 3, 2021 – We at Treatment Action Group (TAG) deeply mourn the loss of Marco Castro-Bojorquez, a visionary HIV and human rights activist, artist, and filmmaker. Marco’s light shined brightly throughout his work and lifted up all around him. His work at the intersection of HIV and migrant and undocumented rights, and economic and language justice, was especially important. RESEARCH IN ACTION AWARDS 2020 Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progressand justice.
ADDRESSING BARRIERS TO ENGAGEMENT WITH FAITH COMMUNITIES On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative. STAFF – TREATMENT ACTION GROUP CONTACT Treatment Action Group 90 Broad Street, Suite 2503 New York, NY 10004 212-253-7922 tag@treatmentactiongroup.org 2020 TAG ANNUAL REPORT PROGRESS IN THE FIGHT PROGRESS IN THE FIGHT For Better Treatment, Prevention, a Vaccine, and a Cure for HIV, Tuberculosis, and Hepatitis C Virus 2020 TAG ANNUALREPORT
ADHERENCE FACT SHEET Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health. This fact sheet is about adherence to hepatitis C treatment. It may be helpful for other medications, whether you are taking them for a short time,or for
skip to Main Content tag@treatmentactiongroup.orgEMAIL SIGNUP
* About Us
* Mission
* History
* Board
* Staff
* Work With Us
* Annual Reports
* Conflicts of Interest* COVID-19
* About the COVID-19 Project * COVID-19 Project News* COVID-19 Pipeline
* COVID-19 Myth Busters * COVID-19 Resources* HIV
* HIV Project News
* About the HIV Project * Basic Science, Vaccines, and Cure * Cure-Related Research Resources* Blog
* Immunologic Nonresponders* HIV & Aging
* End the Epidemic
* HCV
* HCV Project News
* About the HCV Project* TB
* TB Project News
* About the TB Project* Resources
* TAGline
* Pipeline Report
* TB Research Funding Trends * Webinars / Presentations * Letters / Comments * Press / Statements* Support Us
* Donate
* Research in Action Awards 2020 * Limited Art Editions* Join Our List
*
PIPELINE REPORTS
The current ones are all online and available for download now.DECEMBER 7, 2020
2020 REPORT ON TB RESEARCH FUNDING TRENDS_TB R&D REPORT_
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.DECEMBER 2, 2020
INVESTMENT IN HIV RESEARCH PROFOUNDLY BENEFITS THE COVID-19 RESPONSE_PUBLICATION_
This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to endthe HIV epidemic.
NOVEMBER 19, 2020
TAG APPLAUDS DR. DEMETRE DASKALAKIS’ APPOINTMENT AS CDC DIRECTOR OF THE DIVISION OF HIV/AIDS PREVENTION: NYC’S LOSS IS AMERICA’S GAIN_STATEMENT / PRESS_
Treatment Action Group applauds the appointment of Dr. Demetre Daskalakis to helm the U.S. Centers for Disease Control and Prevention (CDC)’s Division of HIV/AIDS Prevention (DHAP). We can think of no better public health practitioner to embody true innovation and disrupt the status quo in our national HIV prevention response.NOVEMBER 16, 2020
RESEARCH TOWARD A CURE TRIALS A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).NOVEMBER 16, 2020
EFFICACY NEWS FROM SECOND COVID-19 VACCINE TRIAL UNDERSCORES NEED FOR TRANSPARENCY AND COOPERATION BETWEEN OUTGOING AND INCOMING USADMINISTRATIONS
_STATEMENT / PRESS_
AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19. Help us ensure that all people with HIV, TB, or HCV receive lifesaving treatment, care, and information.DONATE
CONTACT
Treatment Action Group 90 Broad Street, Suite 2503New York, NY 10004
212-253-7922
tag@treatmentactiongroup.org Copyright © Treatment Action Group. All Rights Reserved. |Privacy Policy
Back To Top
×
* About Us
* Mission
* History
* Board
* Staff
* Work With Us
* Annual Reports
* Conflicts of Interest* COVID-19
* About the COVID-19 Project * COVID-19 Project News* COVID-19 Pipeline
* COVID-19 Myth Busters * COVID-19 Resources* HIV
* HIV Project News
* About the HIV Project * Basic Science, Vaccines, and Cure * Cure-Related Research Resources* Blog
* Immunologic Nonresponders* HIV & Aging
* End the Epidemic
* HCV
* HCV Project News
* About the HCV Project* TB
* TB Project News
* About the TB Project* Resources
* TAGline
* Pipeline Report
* TB Research Funding Trends * Webinars / Presentations * Letters / Comments * Press / Statements* Support Us
* Donate
* Research in Action Awards 2020 * Limited Art Editions* Join Our List
*
AddThis Sharing Sidebar Share to FacebookFacebookShare to TwitterTwitterShare to EmailEmailMore AddThis Share optionsAddThisHide
Show
Close
AddThis
AddThis Sharing
FacebookTwitterEmailAddThisDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0